top of page

Biopharma Pulse - 4/18 - 4/22 Week in Review

  • Writer: BPIQ
    BPIQ
  • Apr 22, 2022
  • 2 min read

As we have reached the middle of April, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.


Table 1. BPIQ company weekly/monthly moves and YTD moves


Category

Weekly Move

YTD Move

All BPIQ Companies

-7.84%

-35.5%

CAR-T Companies

-9.47%

-48.05%

Gene Editing Companies

-10.65%

-47.72%

XBI

-8.70%

-28.69%



Highlights for the week of 4/18-4/22


Biggest positive move

  • $CMPI +331.1% Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types


Biggest negative move

  • $KLDO -53.3%


Additional big moves

  • $VLON +96% Vallon Pharmaceuticals Announces Review of Strategic Alternatives

  • $EVLO +16.8% Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors.

  • $ALVR +15.5% FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients.

  • $NKTR -3.8% Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan.

  • $TRVN -7.42% Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund.

  • $NRXP -13.2% NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress.

  • $MBRX -13.3% Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma.

  • $NVAX -15.4% Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial.

  • $PSTV -16.6% Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights.

  • $SCYX -23.3% SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections.

  • $AMPE -24.3% Receipt of written responses from the United States Food and Drug Administration (FDA) pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.



Highlights for next week

  • To see next week's Big Movers HERE, subscribe. Learn more here.

  • Keep an eye out for upcoming updates on ASCO

  • PDUFA target action dates: $SUPN, $HCM, $CHRS, and $AXSM





See our Big Movers post to learn about upcoming Movers throughout April and PDUFAs, after subscribing. Learn more here.



 
 
 

Comments

bottom of page